These drugs are approved for patients with advanced non-small cell lung cancer:
- Opdivo (nivolumab, a PD-1 inhibitor)
- Keytruda (pembrolizumab, a PD-1 inhibitor) – with a positive PD-L1 biomarker test (more than 1% of cancer cells are positive)
- Tecentriq (atezolizumab, a PD-L1 inhibitor)
Click here for answers to frequently asked questions about immunotherapy for lung cancer.